1496 related articles for article (PubMed ID: 29411536)
1. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
2. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
[TBL] [Abstract][Full Text] [Related]
3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
4. Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Ilié M; Ngo-Mai M; Long-Mira E; Lassalle S; Butori C; Bence C; Hamila M; Hofman V; Hofman P
J Vis Exp; 2018 Sep; (139):. PubMed ID: 30320751
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
[TBL] [Abstract][Full Text] [Related]
9. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
[TBL] [Abstract][Full Text] [Related]
10. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Roach C; Zhang N; Corigliano E; Jansson M; Toland G; Ponto G; Dolled-Filhart M; Emancipator K; Stanforth D; Kulangara K
Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):392-7. PubMed ID: 27333219
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
12. Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC.
Torlakovic E; Albadine R; Bigras G; Boag A; Bojarski A; Cabanero M; Camilleri-Broët S; Cheung C; Couture C; Craddock KJ; Cutz JC; Dhamanaskar P; Fiset PO; Hossain M; Hwang DM; Ionescu D; Itani D; Kelly MM; Kwan K; Lim HJ; Nielsen S; Qing G; Sekhon H; Spatz A; Waghray R; Wang H; Xu Z; Tsao MS
J Thorac Oncol; 2020 Aug; 15(8):1328-1337. PubMed ID: 32304736
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406
[TBL] [Abstract][Full Text] [Related]
16. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G; Huang L; Emancipator K; Nuti S
PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
[TBL] [Abstract][Full Text] [Related]
17. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Wang H; Agulnik J; Kasymjanova G; Fiset PO; Camilleri-Broet S; Redpath M; Cohen V; Small D; Pepe C; Sakr L; Spatz A
Lung Cancer; 2019 Jun; 132():36-38. PubMed ID: 31097091
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
[TBL] [Abstract][Full Text] [Related]
19. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]